As­traZeneca scores again: Calquence ap­proved for CLL as BTK race heats up

Six months af­ter first boast­ing about Phase III da­ta, As­traZeneca has earned ex­pand­ed FDA ap­proval for its BTK in­hibitor Calquence. The drug will now be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.